STOCK TITAN

Veradigm Stock Price, News & Analysis

MDRX Nasdaq

Welcome to our dedicated page for Veradigm news (Ticker: MDRX), a resource for investors and traders seeking the latest updates and insights on Veradigm stock.

Veradigm (MDRX) delivers healthcare technology solutions that connect providers, payers, and patients through integrated data platforms. This news hub provides investors and industry professionals with essential updates on the company’s strategic initiatives and market position.

Access real-time announcements including earnings reports, product innovations, and partnership developments shaping the future of healthcare IT. Our curated collection ensures you stay informed about regulatory milestones, technology deployments, and leadership changes impacting Veradigm ecosystem.

Key updates cover advancements in clinical data interoperability, financial performance metrics, and operational efficiency solutions for healthcare organizations. Bookmark this page for streamlined access to press releases and analysis relevant to MDRX’s role in advancing connected care technologies.

Rhea-AI Summary

Allscripts Healthcare Solutions (NASDAQ: MDRX) will announce its financial results for Q3 2022 after the market closes on November 3, 2022. A conference call to discuss the earnings will follow at 4:30 p.m. ET. The announcement will be immediately available on the Allscripts investor relations website. Participants can join the call by dialing 877-269-7756 or 201-689-7817 with Conference ID # 13733727. A replay will be accessible for one year on the investor relations site.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
-
Rhea-AI Summary

Thomas H. Lee Partners announced the appointment of Paul Black as a consultant for its healthcare investment group. With over 25 years in healthcare IT, Black will assist in identifying and growing investment opportunities. His past roles include CEO of Allscripts (MDRX) and COO of Cerner (CERN). Shahab Vagefi, Managing Director at THL, emphasized Black's experience will enhance their strategy focused on healthcare technology investments. THL has raised over $34 billion and has a history of successful healthcare investments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
management
-
Rhea-AI Summary

Allscripts Healthcare Solutions (NASDAQ: MDRX) will hold a virtual Investor Day on September 28, 2022, at 12:00 p.m. Eastern. The event features presentations from the executive management team and includes a Q&A session. Interested participants can register for the webcast or dial-in via provided links. Presentation slides will be available at approximately 11:30 a.m. Eastern that day on the Allscripts Investor Relations website. A replay will be accessible three hours post-event for six months. For information, visit www.allscripts.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
conferences
Rhea-AI Summary

Veradigm, a healthcare data and technology solutions provider and a unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), has announced a new agreement with Vytalize Health, a Medicare ACO. This collaboration will see Vytalize Health's solutions integrated into the Practice Fusion EHR, enhancing value-based care for primary care physicians. The aim is to improve patient outcomes and reduce healthcare costs through personalized care plans and clinical support. This partnership positions Veradigm at the forefront of the shift toward value-based care in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
Rhea-AI Summary

Veradigm, a unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), has been ranked #1 in Black Book's 2022 survey for Ambulatory Claims Management and Clearinghouse Solutions. Veradigm Payerpath is recognized for its robust revenue cycle management capabilities, achieving a first-pass clean claims rate exceeding 98% and interfacing with over 3,100 payers. This award highlights Veradigm's commitment to improving healthcare connections and enhancing practice profitability. The Black Book ranking emphasizes operational excellence across 18 performance areas, based on user feedback.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
none
Rhea-AI Summary

Allscripts Healthcare Solutions (MDRX) reported a 10% increase in year-to-date bookings, totaling $172 million. The second quarter of 2022 saw revenues of $151 million, up from $141 million in 2021. Veradigm's revenue rose to $145 million, a gain from $133 million YoY. Despite a GAAP loss from operations of $5 million, adjusted EBITDA improved to $39 million. The company affirms its financial outlook for 2022, projecting 6-7% revenue growth and free cash flow between $110-120 million. Stock repurchases amounted to $94 million in Q2.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.46%
Tags
none
-
Rhea-AI Summary

Allscripts Healthcare Solutions (NASDAQ: MDRX) is set to report its financial results for Q2 2022 on August 4, 2022, after market close. The announcement will include details on the earnings call scheduled for 4:30 PM ET the same day. The earnings announcement will be available on Allscripts' investor relations website. Investors can join the call via phone or through the website. A replay will be accessible for six months post-call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
-
Rhea-AI Summary

Pulse8 has announced that its Qualit8 solution achieved MY2022 Measure Certification from the National Committee for Quality Assurance (NCQA) for the third consecutive year. This certification highlights the solution’s commitment to enhancing administrative efficiency and delivering value to health plan customers. The NCQA-Certified HEDIS Measurement Program offers various certifications, including Health Plan Measures and Hybrid Sampling. Veradigm's dedication to transparent analytics aims to reduce healthcare spending and waste while improving efficiency for its clients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
none
Rhea-AI Summary

Veradigm, a unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), has received a patent for its innovative "Dynamic Intervention Planning" method. This system enhances risk adjustment programs by enabling clients to identify, assess, and prioritize opportunities effectively. According to Tom Langan, the company aims to reduce waste and improve accuracy in revenue predictions, thereby allowing better management of client programs. Veradigm uniquely positions itself in the market by controlling significant aspects of risk adjustment, which can lead to greater financial returns for health plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
none

FAQ

What is the current stock price of Veradigm (MDRX)?

The current stock price of Veradigm (MDRX) is $4.5 as of June 24, 2025.

What is the market cap of Veradigm (MDRX)?

The market cap of Veradigm (MDRX) is approximately 484.4M.
Veradigm

Nasdaq:MDRX

MDRX Rankings

MDRX Stock Data

484.38M
104.36M
2.91%
40.9%
Health Information Services
Healthcare
Link
United States
Chicago